MedTrace Logo

Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep

NCT02150616 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-02-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on breathing and sleep of patients with pulmonary hypertension or with interstitial lung disease.

Conditions

Interventions

BEHAVIORAL

Moderate altitude sojourn

Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days

BEHAVIORAL

Low altitude sojourn

Low altitude baseline evaluations will be performed during a stay at Zurich (490)

DRUG

Oxygen

Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

DRUG

Sham oxygen (room air)

Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch, MD · University Hospital, Zürich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02150616 on ClinicalTrials.gov